Search PubMed⌕ Search

PubMed · 16511616

Cell handling using microstructured membranes.

Abstract

Gentle and precise handling of cell suspensions is essential for scientific research and clinical diagnostic applications. Although different techniques for cell analysis at the micro-scale have been proposed, many still require that preliminary sample preparation steps be performed off the chip. Here we present a microstructured membrane as a new microfluidic design concept, enabling the implementation of common sample preparation procedures for suspensions of eukaryotic cells in lab-on-a-chip devices. We demonstrate the novel capabilities for sample preparation procedures by the implementation of metered sampling of nanoliter volumes of whole blood, concentration increase up to three orders of magnitude of sparse cell suspension, and circumferentially uniform, sequential exposure of cells to reagents. We implemented these functions by using microstructured membranes that are pneumatically actuated and allowed to reversibly decouple the flow of fluids and the displacement of eukaryotic cells in suspensions. Furthermore, by integrating multiple structures on the same membrane, complex sequential procedures are possible using a limited number of control steps.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Daniel Irimia, Mehmet Toner. 2006-02-08. Cell handling using microstructured membranes.. https://doi.org/10.1039/b515983k

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A macrokinetic model for myeloma cell culture based on stoichiometric balance.

A macrokinetic model for a myeloma cell line is proposed. The model describes the dynamic balances of lactate, alanine, ATP and NADH during the metabolsim of glucose, glutamine and other amino acids. The metabolic pathways mainly include glycolysis, glutaminolysis, the trcicarboxylic acid cycle, the formation and utilization of amino acids, the respiratory chain, cell growth and cell death. The metabolic shift of glucose is especially considered because of a change in the rate of glycolysis. Thus the model functions in three modes to describe the behaviour of the myeloma cell line. On the basis of this model the macrokinetic bioreaction rates such as the specific substrate consumption rate, the specific growth rate, the specific acetyl-CoA formation rate, as well as the specific oxygen uptake rate, are estimated. The specific substrate consumption rate and the specific growth rate are then coupled into a bioreactor model such that the key variables, i.e., the cell density, the substrate and metabolite concentrations, are obtained. Experiments with batch and fed-batch cultures of a myeloma cell line (X63-Ag8.653) were used to validate the model. The prediction of the model was simulated by the rolling prediction approach.

Cell Line, Tumor↗

The major subtypes of human B-cell lymphomas lack mutations in BCL-2 family member BAD.

Members of the BCL-2 gene family are well known for their role in the pathogenesis of B-cell lymphomas in humans and in mouse models. A recent report that knockout mice deficient for the proapoptotic BCL-2 family member gene BAD frequently develop B-cell lymphomas prompted us to analyze a large collection of human B-cell lymphomas for inactivating mutations in the BAD gene. All 3 exons of the BAD gene were amplified and directly sequenced. The 81 lymphomas analyzed included 16 cases of B-cell chronic lymphocytic leukemia, 11 mantle-cell lymphomas, 10 follicular lymphomas, 7 MALT lymphomas, 8 Burkitt's lymphoma cell lines, 3 cell lines of multiple myeloma, 15 cases and 4 cell lines of diffuse large B-cell lymphoma and 7 Hodgkin's lymphoma lines. No mutations were found in any of the cases. We conclude that mutations in the BAD gene do not play a role in the pathogenesis of the major subtypes of human B-cell lymphomas.

Cell Line, Tumor↗

Methotrexate resistance in vitro is achieved by a dynamic selectionprocess of tumor cell variants emerging during treatment.

Genetic instability leads to tumor heterogeneity, which in turn provides a source of cell variants responsible for drug resistance. However, the source of resistant cells during the process of acquired resistance is poorly understood. Our aim has been to characterize the mechanism by which acquired resistance to methotrexate emerges during the course of cancer cell treatment in vitro. We recently demonstrated that, in vitro, HT-29 colon cancer cells become transiently sensitive to methotrexate by depleting the extracellular milieu of survival factors; on the other hand, the cell population under treatment can reversibly adapt to grow below a critical cell density in the presence of the drug. Here, we show that this adapted cell population gives rise to permanent resistant populations through repeated cycles of cell death and growth. This increased cell turnover, but not merely cell proliferation, is required for the appearance of increasing degrees of stable resistance that are progressively selected by drug pressure. Such a process, taking place in multiple steps, is here designated "dynamic selection." The analysis of sensitive and resistant HT-29 cell populations revealed that methotrexate induces genomic instability--characterized by centrosome amplification and aberrant chromosome recombination--leading to a low-level amplification of the 5q chromosome arm as one of the earliest genetic events selected during treatment. Therefore, this model provides a mechanism by which a tumor cell population lacking resistant subpopulations before treatment is able to acquire the genetic changes required for stable drug resistance.

Cell Line, Tumor↗